The dilemma with normal tension glaucoma treatment

Article

Curcumin: A possible candidate for neuroprotection in glaucoma?

There are several contributing factors that lead to us facing a dilemma in our treatment of normaltension glaucoma (NTG) patients. It is known that at least a third of our glaucoma patients, both in Europe and the US, have normal pressures but currently treatment still involves lowering intraocular pressure (IOP), which is possible to about 30% with surgery only. Even with this reduction in IOP there is still a large amount of patients progressing.1

Additionally, normal methods of treatment of glaucoma patients who have elevated IOP, such as monitoring and preventing nocturnal dips of systemic blood pressure doesn't help in NTG patients as most have low blood pressures. Even though we have had the first indications that neuroprotection beyond IOP reduction is now possible there are too many allergic reactions with Brimonidine,2 so there is a need for real neuroprotection.

Natural compounds: An option

There are currently 33 NIH-sponsored trials involving Curcumin.

Curcumin

Studies of Curcumin have increased exponentially in recent years and over 2000 papers have been published since 2000. These studies demonstrated that Curcumin has antioxidant, antibacterial, antiviral, antifungal, antiinflammatory and antiproliferative as well as proapoptotic effects. Potential therapeutic effects of this compound on various diseases, including neurodegenerative, cardiovascular, pulmonary, metabolic or immunerelated diseases, malignancies and infectious diseases, including AIDS, have been suggested. The biology of the effects of Curcumin has been under intensive study and curcumin is now known to have numerous molecular targets. Diseases for which there are ongoing clinical trials with Curcumin include Alzheimer's disease (AD), psoriasis vulgaris, multiple myeloma, pancreatic cancer, familial adenomatous polyposis, and sporadic adenomatous polyps of the colon.3

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.